PhaseBio Diabetes Program Reaches Inflection Point With Series B Add-On
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held biotech announces an additional $23 million raise from existing investors to finance a head-to-head Phase IIb trial for its GLP-1 analogue against Victoza.